DENND1A

DENND1A rs2479106 — The Androgen Gene Switch Linked to PCOS Risk

Polycystic ovary syndrome affects 5–15% of women of reproductive age and is the leading
cause of anovulatory infertility worldwide. One of its defining features is
hyperandrogenism | excess androgen production, typically from ovarian theca cells, causing
irregular periods, hirsutism, and impaired follicle maturation.
A landmark 2011 genome-wide association study identified a cluster of variants in the
DENND1A gene at chromosome 9q33.3 as among the first confirmed PCOS susceptibility loci —
with rs2479106 carrying an odds ratio of 1.34 (P=8.12×10⁻¹⁹) in over 10,000 Han Chinese
women. Subsequent functional work has revealed why this locus matters: DENND1A directly
controls the theca cell machinery that produces androgens.

The Mechanism

DENND1A encodes DENN domain-containing protein 1A | a guanine nucleotide exchange factor
involved in endosomal trafficking and membrane receptor recycling.
The protein has an alternatively spliced isoform, DENND1A.V2, that is markedly overexpressed
in the theca cells of women with PCOS. When researchers forced expression of DENND1A.V2 in
normal theca cells, the cells acquired a PCOS-like phenotype: they upregulated
CYP17A1 | steroid-17α-hydroxylase/17,20 lyase, the rate-limiting enzyme in androgen
biosynthesis and CYP11A1 (cholesterol
side-chain cleavage enzyme), producing excess androgens and progestins. Conversely,
knocking out DENND1A.V2 reduced these enzymes and suppressed androgen output.

The rs2479106 variant sits in an intron of the DENND1A gene, spanning a region containing
at least 38 candidate regulatory elements between introns 2 and 6 | identified by ATAC-seq
and ENCODE enhancer overlap in a 2024/2025 study.
Epigenetic activation of these intronic enhancers using dCas9-P300 produced 1.7–3.2-fold
increases in testosterone in adrenal cell models. The rs2479106 locus thus marks a
region of the genome that regulates how much DENND1A is expressed in steroidogenic
cells — and consequently how much androgen those cells produce.

The Evidence

The original discovery was made in a staged GWAS by Chen et al. 2011 in Nature Genetics |
discovery cohort: 744 PCOS cases/895 controls; two replication cohorts totaling 3,338 PCOS
cases/5,792 controls; all Han Chinese. The G
allele at rs2479106 conferred an odds ratio of 1.34 at a combined P-value of 8.12×10⁻¹⁹ —
statistical confidence well beyond genome-wide significance.

A 2013 genotype-phenotype study of over 2,000 Han Chinese PCOS women found that carriers
of the G allele (GG+AG genotype) had significantly elevated serum insulin levels 2 hours
after a 75g oral glucose challenge | P=0.02, dominant model, suggesting impaired post-load
insulin clearance or early insulin secretory dysfunction.
A 2020 follow-up in 2,082 PCOS women refined this: the AA genotype (no G alleles) was
actually associated with a higher rate of insulin resistance (53.6% vs 48.3%; OR 0.80
for GG+AG, P=0.036 after age/BMI adjustment), though this association disappeared when
subjects with a family history of diabetes were excluded — suggesting complex confounding.

Meta-analyses confirm population-specific effects. Gao et al. 2016 (8 studies, 8,185
cases/28,675 controls) found a significant
association in Asian populations (OR 1.32, 95% CI 1.25–1.39) but not in European
populations (OR 1.01). Similarly, a 2012 replication study in Caucasian European cohorts
(1,144 cases/17,635 controls) found OR 1.05 (P=0.45) for rs2479106, while the neighboring
SNP rs10818854 replicated strongly with P=9.8×10⁻⁸. This suggests rs2479106 is a tag SNP
that tracks the causal variant in Asian populations through linkage disequilibrium, but
that LD pattern differs across ancestries.

A 2023 meta-analysis by Larsen et al. (10 studies, 3,627 cases/20,325 controls) |
including subgroup analyses by ancestry and genetic model
found the Asian subgroup recessive model showed OR 1.84 (P=0.006), and the overall
dominant model approached significance at OR 1.31 (P=0.05).

Separately, a 2025 Nature Communications study from Mount Sinai and Duke University |
using ATAC-seq, allele-specific reporter assays, and dCas9-P300 epigenetic editing in
human PCOS theca cell models identified 4
regulatory variants in the DENND1A locus with allele-specific activity,
providing the first direct molecular evidence that inherited variants in this region
can dysregulate DENND1A expression and drive testosterone overproduction.

Practical Actions

For women carrying the G allele — particularly those of East or Southeast Asian ancestry
where this variant has the strongest population-level effect — rs2479106 adds to the
evidence base for earlier reproductive endocrinology evaluation if PCOS symptoms are present.
Specific monitoring for androgen excess (total and free testosterone, DHEAS,
androstenedione) and post-load insulin dysregulation (2-h glucose tolerance test) is
warranted, as these are the phenotypic features most consistently associated with
G-allele carriage in published cohorts.

PCOS management strategies that specifically address androgen-driven ovulatory dysfunction
include inositol supplementation (myo-inositol reduces androgens and improves ovulatory
function through insulin-sensitizing pathways) and anti-androgen monitoring at reproductive
transitions (puberty, pregnancy planning, perimenopause).

Interactions

rs10818854 and rs10986105 (DENND1A): These two neighboring DENND1A variants show
stronger and more consistent PCOS association in European populations (OR 1.36 and 1.39
respectively in meta-analyses, P<0.001 in European cohorts). rs10818854 and rs10986105
are in high LD with each other (r²>0.65) but not strongly with rs2479106. The three
variants capture different aspects of risk in different ancestral LD structures.

rs6166 (FSHR N680S): The FSH receptor sensitivity variant interacts with PCOS
susceptibility at the ovarian level. Women with PCOS-associated genotypes at DENND1A
(excess androgen production) and low FSH receptor sensitivity (FSHR GG) may face a
double challenge: impaired follicle development from reduced FSH response AND
hyperandrogenic suppression of folliculogenesis. Combined profiling of DENND1A +
FSHR may better characterize ovarian response to stimulation in a PCOS context.
This is a proposed compound interaction — no published clinical trial has formally
tested this combination.

rs13405728 (LHCGR): Another PCOS GWAS locus, the LH/hCG receptor. Elevated LH
in PCOS drives theca cell androgen production through LHCGR; carriers of risk alleles
at both DENND1A and LHCGR may have a compounding androgenic phenotype. Published data
from the Chen 2011 GWAS identified both loci simultaneously, but compound effects of
carrying risk alleles at both have not been quantified in published studies.